Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Elevated in vivo markers of presynaptic striatal dopamine activity have been a consistent finding in schizophrenia, and include a large effect size elevation in dopamine synthesis capacity. However, it is not known if the dopaminergic dysfunction is limited to the striatal terminals of dopamine neurons, or is also evident in the dopamine neuron cell bodies, which mostly originate in the substantia nigra. The aim of our studies was therefore to determine whether dopamine synthesis capacity is altered in the substantia nigra of people with schizophrenia, and how this relates to symptoms. In a post-mortem study, a semi-quantitative analysis of tyrosine hydroxylase staining was conducted in nigral dopaminergic cells from post-mortem tissue from patients with schizophrenia (n = 12), major depressive disorder (n = 13) and matched control subjects (n = 13). In an in vivo imaging study, nigral and striatal dopaminergic function was measured in patients with schizophrenia (n = 29) and matched healthy control subjects (n = 29) using (18)F-dihydroxyphenyl-L-alanine ((18)F-DOPA) positron emission tomography. In the post-mortem study we found that tyrosine hydroxylase staining was significantly increased in nigral dopaminergic neurons in schizophrenia compared with both control subjects (P < 0.001) and major depressive disorder (P < 0.001). There was no significant difference in tyrosine hydroxylase staining between control subjects and patients with major depressive disorder, indicating that the elevation in schizophrenia is not a non-specific indicator of psychiatric illness. In the in vivo imaging study we found that (18)F-dihydroxyphenyl-L-alanine uptake was elevated in both the substantia nigra and in the striatum of patients with schizophrenia (effect sizes = 0.85, P = 0.003 and 1.14, P < 0.0001, respectively) and, in the voxel-based analysis, was elevated in the right nigra (P < 0.05 corrected for family wise-error). Furthermore, nigral (18)F-dihydroxyphenyl-L-alanine uptake was positively related with the severity of symptoms (r = 0.39, P = 0.035) in patients. However, whereas nigral and striatal (18)F-dihydroxyphenyl-L-alanine uptake were positively related in control subjects (r = 0.63, P < 0.001), this was not the case in patients (r = 0.30, P = 0.11). These findings indicate that elevated dopamine synthesis capacity is seen in the nigral origin of dopamine neurons as well as their striatal terminals in schizophrenia, and is linked to symptom severity in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These techniques indicate that striatal dopamine synthesis, storage and release are elevated in patients with psychosis compared to healthy controls (HC) (45-48) with large effect sizes (49).”
From Aberrant Salience, Information Processing, and Dopaminergic Signaling in People at Clinical High Risk for Psychosis (2020) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567 · cited 1×
“A Patlak graphical analysis was used to calculate the influx constant (K cer i value) for the specific uptake of 18 F-DOPA in the regions of interest relative to uptake in the reference region (Patlak et al., 1983).”
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Self-citationDopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018 · cited 1×
“The dopamine hypothesis of schizophrenia proposes that subcortical dopamine dysfunction underlies the illness (Davis et al., 1991; Howes and Kapur, 2009).”
Haber, S. N., Fudge, J. L., & McFarland, N. R. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-06-02369.2000 · Cited by 1,610 · cited 1×
“…evidence indicates that these alterations in dopamine function are particularly apparent in the associative subdivision of the striatum (Howes et al., 2009b; Kegeles et al., 2010), which predominantly receives projections from the substantia nigra (Haber et al., 2000, 2006; Joel and Weiner, 2000).”
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291 · cited 2×
“…al., 2012; Roiser et al., 2012; Yoon et al., 2013) and the consistent evidence for increased dopamine release in the striatal terminal regions [see (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 2000) and meta-analysis (Howes et al., 2012b)], it seems likely that this reflects an…”
Ollinger, J. M., & Fessler, J. A. (1997) · IEEE Signal Processing Magazine · doi:10.1109/79.560323 · Cited by 1,167
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · cited 2×
“…Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated baseline and stimulated striatal dopamine levels (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 1998, 2000, 2009; Mizrahi et al., 2012).”
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · cited 2×
“…2013) and the consistent evidence for increased dopamine release in the striatal terminal regions [see (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 2000) and meta-analysis (Howes et al., 2012b)], it seems likely that this reflects an increase in midbrain dopamine neuron…”
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967 · cited 3×
“In the schizophrenia group the mean (SD) symptom severity scores were: total symptoms = 77.6 (47.6); positive symptoms = 38.3 (30); affective symptoms = 2.0 (3.9); negative symptoms = 31.9 (22.9).”
InfluentialSelf-citationIncreased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort
Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R. M., Seibyl, J. P., Bowers, M., van Dyck, C. H., Charney, D. S., Innis, R. B., & Laruelle, M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.761 · Cited by 803 · cited 1×
“…Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated baseline and stimulated striatal dopamine levels (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 1998, 2000, 2009; Mizrahi et al., 2012).”
Tyrosine, Phenylalanine, and Catecholamine Synthesis and Function in the Brain2
Fernstrom, J. D., & Fernstrom, M. H. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.6.1539s · Cited by 755 · cited 2×
“Both enzymes are regulated, but the rate limiting step in dopamine synthesis is the conversion of tyrosine to dihydroxyphenyl-L-alanine (Zhu et al., 1993; Cumming et al., 1995, 1997; Fernstrom and Fernstrom, 2007).”
Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.514 · Cited by 744 · cited 8×
“However, it is not elevated in non-psychotic depression (Martinot et al., 2001) or in people with persistent subclinical psychotic symptoms who have not developed a psychotic disorder (Howes et al., 2011b, 2013), suggesting specificity to psychotic illness (Howes et al., 2007, 2009a).”
InfluentialSelf-citationHaber, S. N., Kim, K.-S., Mailly, P., & Calzavara, R. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0271-06.2006 · Cited by 686 · cited 1×
“…evidence indicates that these alterations in dopamine function are particularly apparent in the associative subdivision of the striatum (Howes et al., 2009b; Kegeles et al., 2010), which predominantly receives projections from the substantia nigra (Haber et al., 2000, 2006; Joel and Weiner, 2000).”
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia
Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M., Weinberger, D. R., & Berman, K. F. (2002) · Nature Neuroscience · doi:10.1038/nn804 · Cited by 652 · cited 1×
“…( 18 F-DOPA; Reith et al., 1994; Hietala et al., 1995, 1999; Dao-Castellana et al., 1997; Lindstrom et al., 1999; Elkashef et al., 2000; Meyer-Lindenberg et al., 2002; McGowan et al., 2004; Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et…”
Joel, D., & Weiner, I. (2000) · Neuroscience · doi:10.1016/s0306-4522(99)00575-8 · Cited by 614 · cited 1×
“…evidence indicates that these alterations in dopamine function are particularly apparent in the associative subdivision of the striatum (Howes et al., 2009b; Kegeles et al., 2010), which predominantly receives projections from the substantia nigra (Haber et al., 2000, 2006; Joel and Weiner, 2000).”
Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565 · cited 4×
“Nevertheless, the smallest alteration was seen in the limbic striatum, in keeping with the previous studies (Howes et al., 2009b, 2011b; Kegeles et al., 2010).”
InfluentialSubstantia nigra/ventral tegmental reward prediction error disruption in psychosis
Murray, G. K., Corlett, P. R., Clark, L., Pessiglione, M., Blackwell, A. D., Honey, G., Jones, P. B., Bullmore, E. T., Robbins, T. W., & Fletcher, P. C. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002058 · Cited by 532 · cited 2×
“…the functional MRI evidence of abnormal nigro-striatal activation in schizophrenia and its prodrome in the context of reward/conditioning tasks (Murray et al., 2008; Waltz et al., 2009; Romaniuk et al., 2010; Gradin et al., 2011; Allen et al., 2012a, b; Nielsen et al., 2012; Roiser et al.,…”
InfluentialExpected value and prediction error abnormalities in depression and schizophrenia
Gradin, V. B., Kumar, P., Waiter, G., Ahearn, T., Stickle, C., Milders, M., Reid, I., Hall, J., & Steele, J. D. (2011) · Brain · doi:10.1093/brain/awr059 · Cited by 485 · cited 2×
“…in schizophrenia and its prodrome in the context of reward/conditioning tasks (Murray et al., 2008; Waltz et al., 2009; Romaniuk et al., 2010; Gradin et al., 2011; Allen et al., 2012a, b; Nielsen et al., 2012; Roiser et al., 2012; Yoon et al., 2013) and the consistent evidence for increased…”
InfluentialLodge, D. J., & Grace, A. A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2847-07.2007 · Cited by 449 · cited 2×
“In the schizophrenia group the mean (SD) symptom severity scores were: total symptoms = 77.6 (47.6); positive symptoms = 38.3 (30); affective symptoms = 2.0 (3.9); negative symptoms = 31.9 (22.9).”
InfluentialDopamine Synthesis Capacity Before Onset of Psychosis: A Prospective [ 18 F]-DOPA PET Imaging Study
Howes, O. D., Bose, S. K., Turkheimer, F., Valli, I., Egerton, A., Valmaggia, L. R., Murray, R. M., & McGuire, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010160 · Cited by 343 · cited 4×
“Nevertheless, the smallest alteration was seen in the limbic striatum, in keeping with the previous studies (Howes et al., 2009b, 2011b; Kegeles et al., 2010).”
InfluentialSelf-citationElevated dopa decarboxylase activity in living brain of patients with psychosis
Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., & Dyve, S. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11651 · Cited by 342 · cited 2×
“Specifically schizophrenia is associated with elevations in striatal dopamine synthesis capacity, as measured using the PET radiotracers L-[b- 11 C]-dihydroxyphenyl-L-alanine or 6-[ 18 F]fluoro-dihydroxyphenyl-L-alanine ( 18 F-DOPA; Reith et al., 1994; Hietala et al., 1995, 1999; Dao-Castellana et al., 1997; Lindstrom…”
Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia
Demjaha, A., Murray, R. M., McGuire, P. K., Kapur, S., & Howes, O. D. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010144 · Cited by 325 · cited 1×
“…et al., 2002; McGowan et al., 2004; Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated baseline and stimulated striatal dopamine levels (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al.,…”
Self-citationPresynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients
Hietala, J., Syvälahti, E., Kuoppamäki, M., Hietala, J., Syvälahti, E., Haaparanta, M., Kuoppamäki, M., Ruotsalainen, U., Vuorio, K., Räkköläinen, V., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91801-9 · Cited by 321 · cited 2×
“An abnormality in the reference region is also unlikely to explain the results as previous studies have reported elevated striatal dopamine synthesis capacity in schizophrenia using other reference regions (Hietala et al., 1995; McGowan et al., 2004).”
Howes, O., Bose, S., Turkheimer, F., Valli, I., Egerton, A., Stahl, D., Valmaggia, L., Allen, P., Murray, R., & McGuire, P. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.20 · Cited by 292 · cited 6×
“However, it is not elevated in non-psychotic depression (Martinot et al., 2001) or in people with persistent subclinical psychotic symptoms who have not developed a psychotic disorder (Howes et al., 2011b, 2013), suggesting specificity to psychotic illness (Howes et al., 2007, 2009a).”
InfluentialSelf-citationLindström, L. H., Gefvert, O., Hagberg, G., Lundberg, T., Bergström, M., Hartvig, P., & Långström, B. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00109-2 · Cited by 284 · cited 1×
“…or 6-[ 18 F]fluoro-dihydroxyphenyl-L-alanine ( 18 F-DOPA; Reith et al., 1994; Hietala et al., 1995, 1999; Dao-Castellana et al., 1997; Lindstrom et al., 1999; Elkashef et al., 2000; Meyer-Lindenberg et al., 2002; McGowan et al., 2004; Kumakura et al., 2007; Bose et al., 2008; Howes…”
Increased stress-induced dopamine release in psychosis
Mizrahi, R., Addington, J., Rusjan, P. M., Suridjan, I., Ng, A., Boileau, I., Pruessner, J. C., Remington, G., Houle, S., & Wilson, A. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.10.009 · Cited by 277 · cited 1×
“…Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated baseline and stimulated striatal dopamine levels (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 1998, 2000, 2009; Mizrahi et al., 2012).”
Egerton, A., Chaddock, C. A., Winton-Brown, T. T., Bloomfield, M. A. P., Bhattacharyya, S., Allen, P., McGuire, P. K., & Howes, O. D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.017 · Cited by 253 · cited 1×
“Increased striatal dopamine synthesis capacity is also evident in individuals with prodromal symptoms of schizophrenia, suggesting that the dopaminergic abnormality predates the onset of frank psychosis (Howes et al., 2009b, 2011a,b; Egerton et al., 2013).”
Self-citationDepressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia
Hietala, J., Syvälahti, E., Vilkman, H., Vuorio, K., Räkköläinen, V., Bergman, J., Haaparanta, M., Solin, O., Kuoppamäki, M., Eronen, E., et al. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00113-3 · Cited by 243 · cited 2×
“Furthermore, no difference in 18 F-DOPA metabolism under carbidopa blockade has been found between patients with schizophrenia and control subjects (Hietala et al., 1999).”
Howes, O., Egerton, A., Allan, V., McGuire, P., Stokes, P., & Kapur, S. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788957528 · Cited by 239 · cited 8×
“However, it is not elevated in non-psychotic depression (Martinot et al., 2001) or in people with persistent subclinical psychotic symptoms who have not developed a psychotic disorder (Howes et al., 2011b, 2013), suggesting specificity to psychotic illness (Howes et al., 2007, 2009a).”
InfluentialSelf-citationMcGowan, S., Lawrence, A. D., Sales, T., Quested, D., & Grasby, P. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.2.134 · Cited by 226 · cited 2×
“An abnormality in the reference region is also unlikely to explain the results as previous studies have reported elevated striatal dopamine synthesis capacity in schizophrenia using other reference regions (Hietala et al., 1995; McGowan et al., 2004).”
Functional imaging of the human dopaminergic midbrain
Düzel, E., Bunzeck, N., Guitart-Masip, M., Wittmann, B., Schott, B. H., & Tobler, P. N. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.02.005 · Cited by 216 · cited 1×
“However, as the midbrain region of interest was an order of magnitude larger than the substantia nigra (Ahsan et al., 2007; Duzel et al., 2009), it is unclear from this study whether the abnormalities reported represent dysregulated nigral dopaminergic function or dysfunction in other midbrain…”
Abi-Dargham, A., van de Giessen, E., Slifstein, M., Kegeles, L. S., & Laruelle, M. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.12.007 · Cited by 213 · cited 1×
“…Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated baseline and stimulated striatal dopamine levels (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 1998, 2000, 2009; Mizrahi et al., 2012).”
Alterations of the Brain Reward System in Antipsychotic Naïve Schizophrenia Patients
Nielsen, M. Ø., Rostrup, E., Wulff, S., Bak, N., Lublin, H., Kapur, S., & Glenthøj, B. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.007 · Cited by 210 · cited 2×
“…between groups in cigarette consumption or alcohol use [median (IQR) cigarette use for control subjects = 0.1 (7) and schizophrenia 5 0.1 (10) cigarettes/day, Z = 0.6, P = 0.54; median (IQR) alcohol use for control subjects = 6 (10) and schizophrenia = 2 (8) units/week, Z = 1.2, P = 0.24].”
InfluentialNeural and Behavioral Correlates of Aberrant Salience in Individuals at Risk for Psychosis
Roiser, J. P., Howes, O. D., Chaddock, C. A., Joyce, E. M., & McGuire, P. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs147 · Cited by 205 · cited 2×
“…between groups in cigarette consumption or alcohol use [median (IQR) cigarette use for control subjects = 0.1 (7) and schizophrenia 5 0.1 (10) cigarettes/day, Z = 0.6, P = 0.54; median (IQR) alcohol use for control subjects = 6 (10) and schizophrenia = 2 (8) units/week, Z = 1.2, P = 0.24].”
InfluentialSelf-citationBogerts, B., Häntsch, J., & Herzer, M. (1983) · PubMed · Cited by 197
Martinot, M.-L. P., Bragulat, V., Artiges, E., Dollé, F., Hinnen, F., Jouvent, R., & Martinot, J.-L. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.314 · Cited by 194 · cited 1×
“However, it is not elevated in non-psychotic depression (Martinot et al., 2001) or in people with persistent subclinical psychotic symptoms who have not developed a psychotic disorder (Howes et al., 2011b, 2013), suggesting specificity to psychotic illness (Howes et al., 2007, 2009a).”
Toru, M., Watanabe, S., Shibuya, H., Nishikawa, T., Noda, K., Mitsushio, H., Ichikawa, H., Kurumaji, A., Takashima, M., Mataga, N., et al. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb06312.x · Cited by 191 · cited 3×
“Our finding of increased nigral tyrosine hydroxylase staining is in agreement with previous findings of increased nigral tyrosine hydroxylase activity (Toru et al., 1988) and tyrosine hydroxylase messenger RNA levels in schizophrenia (Mueller et al., 2004).”
Waltz, J. A., Schweitzer, J. B., Gold, J. M., Kurup, P. K., Ross, T. J., Jo Salmeron, B., Rose, E. J., McClure, S. M., & Stein, E. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.214 · Cited by 186 · cited 2×
“Given the functional MRI evidence of abnormal nigro-striatal activation in schizophrenia and its prodrome in the context of reward/conditioning tasks (Murray et al., 2008; Waltz et al., 2009; Romaniuk et al., 2010; Gradin et al., 2011; Allen et al., 2012a, b; Nielsen et al., 2012; Roiser et al., 2012; Yoon et al., 201…”
Smith, Y., & Villalba, R. (2008) · Movement Disorders · doi:10.1002/mds.22027 · Cited by 186
Cannabis-Induced Psychosis-Like Experiences Are Associated with High Schizotypy
Barkus, E. J., Stirling, J., Hopkins, R. S., & Lewis, S. (2006) · Psychopathology · doi:10.1159/000092678 · Cited by 167 · cited 1×
“Additionally all subjects received assessment of recreational exposure to psychoactive substances by semi-structured questionnaire [modified from Barkus et al. (2006)].”
Gill, K. M., Lodge, D. J., Cook, J. M., Aras, S., & Grace, A. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.76 · Cited by 162 · cited 1×
“A proof-of-concept for this has been shown using a GABA-alpha 5 receptor selective agent, which altered the hippocampal drive to the midbrain and was found to reverse aberrant midbrain dopamine neuronal functioning in rodent models of schizophrenia (Gill et al., 2011).”
Presynaptic dopaminergic function in the striatum of schizophrenic patients
Dao-Castellana, M.-H., Paillère-Martinot, M.-L., Hantraye, P., Attar-Lévy, D., Rémy, P., Crouzel, C., Artiges, E., Féline, A., Syrota, A., & Martinot, J.-L. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00102-8 · Cited by 160 · cited 1×
“…L-[b- 11 C]-dihydroxyphenyl-L-alanine or 6-[ 18 F]fluoro-dihydroxyphenyl-L-alanine ( 18 F-DOPA; Reith et al., 1994; Hietala et al., 1995, 1999; Dao-Castellana et al., 1997; Lindstrom et al., 1999; Elkashef et al., 2000; Meyer-Lindenberg et al., 2002; McGowan et al., 2004; Kumakura et al.,…”
Kumakura, Y., Cumming, P., Vernaleken, I., Buchholz, H.-G., Siessmeier, T., Heinz, A., Kienast, T., Bartenstein, P., & Gründer, G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0805-07.2007 · Cited by 159 · cited 4×
“…et al., 1995, 1999; Dao-Castellana et al., 1997; Lindstrom et al., 1999; Elkashef et al., 2000; Meyer-Lindenberg et al., 2002; McGowan et al., 2004; Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated…”
InfluentialYoon, J. H., Minzenberg, M. J., Raouf, S., D’Esposito, M., & Carter, C. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.018 · Cited by 149 · cited 2×
“…et al., 2008; Waltz et al., 2009; Romaniuk et al., 2010; Gradin et al., 2011; Allen et al., 2012a, b; Nielsen et al., 2012; Roiser et al., 2012; Yoon et al., 2013) and the consistent evidence for increased dopamine release in the striatal terminal regions [see (Laruelle et al., 1996; Breier et…”
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Grasby, P. M., & Mcguire, P. K. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.191.51.s13 · Cited by 142 · cited 2×
“However, it is not elevated in non-psychotic depression (Martinot et al., 2001) or in people with persistent subclinical psychotic symptoms who have not developed a psychotic disorder (Howes et al., 2011b, 2013), suggesting specificity to psychotic illness (Howes et al., 2007, 2009a).”
Self-citationElevated levels of tyrosine hydroxylase in the locus coeruleus in major depression
Zhu, M.-Y., Klimek, V., Dilley, G. E., Haycock, J. W., Stockmeier, C., Overholser, J. C., Meltzer, H. Y., & Ordway, G. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00135-3 · Cited by 137 · cited 1×
“Finally our finding of no alteration in nigral tyrosine hydroxylase staining in patients with major depression extends previous findings in this patient population of altered tyrosine hydroxylase levels in the locus coeruleus (Baumann et al., 1999; Zhu et al., 1999; Gos et al., 2008).”
Kessler, R. M., Woodward, N. D., Riccardi, P., Li, R., Ansari, M. S., Anderson, S., Dawant, B., Zald, D., & Meltzer, H. Y. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.12.029 · Cited by 136 · cited 1×
“…increased dopamine D2, but not D3 or dopamine transporter, availability in the substantia nigra (Arakawa et al., 2009; Graff- Guerrero et al., 2009; Kessler et al., 2009; Mizrahi et al., 2011), these findings indicate that particular aspects of nigral dopaminergic function are abnormal in…”
PET Studies of Cerebral Levodopa Metabolism: A Review of Clinical Findings and Modeling Approaches
Kumakura, Y., & Cumming, P. (2009) · The Neuroscientist · doi:10.1177/1073858409338217 · Cited by 134
Egerton, A., Demjaha, A., McGuire, P., Mehta, M. A., & Howes, O. D. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.12.058 · Cited by 134 · cited 2×
“This approach has shown good reliability in delineating these structures, including after spatial normalization (Egerton et al., 2009).”
Self-citationAllen, P., Luigjes, J., Howes, O. D., Egerton, A., Hirao, K., Valli, I., Kambeitz, J., Fusar-Poli, P., Broome, M., & McGuire, P. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr194 · Cited by 129
Self-citation6-18F-DOPA PET study in patients with schizophrenia
Elkashef, A. M., Doudet, D. J., Bryant, T., Cohen, R. M., Li, S.-H., & Wyatt, R. J. (2000) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(00)00064-0 · Cited by 118 · cited 1×
“…F]fluoro-dihydroxyphenyl-L-alanine ( 18 F-DOPA; Reith et al., 1994; Hietala et al., 1995, 1999; Dao-Castellana et al., 1997; Lindstrom et al., 1999; Elkashef et al., 2000; Meyer-Lindenberg et al., 2002; McGowan et al., 2004; Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et…”
Graff‐Guerrero, A., Mizrahi, R., Agid, O., Marcon, H., Barsoum, P., Rusjan, P., Wilson, A. A., Zipursky, R. B., & Kapur, S. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.199 · Cited by 116
Gründer, G., Vernaleken, I., Müller, M. J., Davids, E., Heydari, N., Buchholz, H., Bartenstein, P., Munk, O. L., Stoeter, P., Wong, D. F., et al. (2002) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300103 · Cited by 115 · cited 2×
“This potential effect of treatment (Grunder et al., 2003) warrants further investigation in a larger sample.”
Volumes, spatial extents and a probabilistic atlas of the human basal ganglia and thalamus
Ahsan, R. L., Allom, R. J., Gousias, I. S., Habib, H., Turkheimer, F., Free, S. L., Lemieux, L., Myers, R., Duncan, J. S., Brooks, D. J., et al. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.06.004 · Cited by 114 · cited 2×
“2A); striatum (left and right sides combined) using the HamNet atlas, a probabilistic atlas of standard brain regions (Ahsan et al., 2007).”
Self-citationMidbrain activation during pavlovian conditioning and delusional symptoms in schizophrenia
Romaniuk, L., Honey, G. D., King, J. R. L., Whalley, H. C., McIntosh, A. M., Levita, L., Hughes, M., Johnstone, E. C., Day, M., Lawrie, S. M., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.169 · Cited by 113 · cited 2×
“…nigro-striatal activation in schizophrenia and its prodrome in the context of reward/conditioning tasks (Murray et al., 2008; Waltz et al., 2009; Romaniuk et al., 2010; Gradin et al., 2011; Allen et al., 2012a, b; Nielsen et al., 2012; Roiser et al., 2012; Yoon et al., 2013) and the consistent…”
InfluentialThe role of dopamine for the pathophysiology of schizophrenia
Meisenzahl, E. M., Schmitt, G. J., Scheuerecker, J., & Möller, H.-J. (2007) · International Review of Psychiatry · doi:10.1080/09540260701502468 · Cited by 110 · cited 1×
“Supporting this there is now a large body of evidence for presynaptic dopaminergic dysfunction in the striatum in schizophrenia (Howes et al., 2007; Meisenzahl et al., 2007; Lyon et al., 2011).”
Ichinose, H., Ohye, T., Fujita, K., Pantucek, F., Lange, K., Riederer, P., & Nagatsu, T. (1994) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02250926 · Cited by 107 · cited 2×
“However, it is important to note that messenger RNA levels have been found to be unaltered in two studies, and, additionally tyrosine hydroxylase protein levels were reduced in one of these studies (Ichinose et al., 1994; Perez-Costas et al., 2012).”
Mueller, H. T., Haroutunian, V. H., Davis, K. L., & Meador‐Woodruff, J. H. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.11.004 · Cited by 102 · cited 2×
“Our finding of increased nigral tyrosine hydroxylase staining is in agreement with previous findings of increased nigral tyrosine hydroxylase activity (Toru et al., 1988) and tyrosine hydroxylase messenger RNA levels in schizophrenia (Mueller et al., 2004).”
Howes, O. D., Shotbolt, P., Bloomfield, M., Daalman, K., Demjaha, A., Diederen, K. M. J., Ibrahim, K., Kim, E., McGuire, P., Kahn, R. S., et al. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr195 · Cited by 91 · cited 1×
“However, it is not elevated in non-psychotic depression (Martinot et al., 2001) or in people with persistent subclinical psychotic symptoms who have not developed a psychotic disorder (Howes et al., 2011b, 2013), suggesting specificity to psychotic illness (Howes et al., 2007, 2009a).”
Self-citationMizrahi, R., Agid, O., Borlido, C., Suridjan, I., Rusjan, P., Houle, S., Remington, G. J., Wilson, A. A., & Kapur, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.005 · Cited by 85 · cited 2×
“To determine if age, sex, or post-mortem interval moderated the effect, a secondary analysis of variance was used to determine the effect of diagnostic group on staining score co-varying for these variables.”
Zhu, M., Juorio, A. V., Paterson, I. A., & Boulton, A. A. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90843-7 · Cited by 79 · cited 1×
“Both enzymes are regulated, but the rate limiting step in dopamine synthesis is the conversion of tyrosine to dihydroxyphenyl-L-alanine (Zhu et al., 1993; Cumming et al., 1995, 1997; Fernstrom and Fernstrom, 2007).”
Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging
Bose, S. K., Turkheimer, F., Howes, O. D., Mehta, M. A., CUNLIFFE, R., Stokes, P. R. A., & Grasby, P. M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.011 · Cited by 79 · cited 1×
“…et al., 1997; Lindstrom et al., 1999; Elkashef et al., 2000; Meyer-Lindenberg et al., 2002; McGowan et al., 2004; Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated baseline and stimulated…”
Self-citationRegional dopamine synthesis in patients with schizophrenia using L-[β-11C]DOPA PET
Nozaki, S., Kato, M., Takano, H., Ito, H., Takahashi, H., Arakawa, R., Okumura, M., Fujimura, Y., Matsumoto, R., Ota, M., et al. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.006 · Cited by 76 · cited 1×
“…1999; Elkashef et al., 2000; Meyer-Lindenberg et al., 2002; McGowan et al., 2004; Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated baseline and stimulated striatal dopamine levels (Laruelle et al.,…”
Regulation of DOPA Decarboxylase Activity in Brain of Living Rat
Cumming, P., Kuwabara, H., Ase, A., & Gjedde, A. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65031381.x · Cited by 76 · cited 1×
“Both enzymes are regulated, but the rate limiting step in dopamine synthesis is the conversion of tyrosine to dihydroxyphenyl-L-alanine (Zhu et al., 1993; Cumming et al., 1995, 1997; Fernstrom and Fernstrom, 2007).”
Reduced tyrosine hydroxylase immunoreactivity in locus coeruleus of suicide victims
Biegon, A., & Fieldust, S. (1992) · Synapse · doi:10.1002/syn.890100111 · Cited by 74 · cited 1×
“Non-disorder specific factors, such as suicide as cause of death, are potential confounds in post-mortem studies of psychiatric disorders (Biegon and Fieldust, 1992).”
Allen, P., Chaddock, C. A., Howes, O. D., Egerton, A., Seal, M. L., Fusar-Poli, P., Valli, I., Day, F., & McGuire, P. K. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr017 · Cited by 74 · cited 1×
“…difference between groups in cigarette consumption or alcohol use [median (IQR) cigarette use for control subjects = 0.1 (7) and schizophrenia 5 0.1 (10) cigarettes/day, Z = 0.6, P = 0.54; median (IQR) alcohol use for control subjects = 6 (10) and schizophrenia = 2 (8) units/week, Z = 1.2, P…”
InfluentialSelf-citationPresynaptic Regulation of Dopamine Transmission in Schizophrenia
Lyon, G. J., Abi-Dargham, A., Moore, H., Lieberman, J. A., Javitch, J. A., & Sulzer, D. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp010 · Cited by 66 · cited 2×
“Supporting this there is now a large body of evidence for presynaptic dopaminergic dysfunction in the striatum in schizophrenia (Howes et al., 2007; Meisenzahl et al., 2007; Lyon et al., 2011).”
Kim, E., Howes, O. D., Turkheimer, F., Kim, B., Jeong, J. M., Kim, J. W., Lee, J. S., Jang, I., Shin, S., Kapur, S., et al. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2953-0 · Cited by 59 · cited 2×
“If this is the case, then it supports the development of treatments that target the control of midbrain dopamine neurons as alternatives to antipsychotics, which target the postsynaptic postsynaptic dopaminergic system (Kim et al., 2012, 2013a).”
Self-citationPérez‐Costas, E., Meléndez‐Ferro, M., Rice, M. W., Conley, R. R., & Roberts, R. C. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00031 · Cited by 58 · cited 3×
“Regional K cer i values in schizophrenic patients versus control subjects were compared using independent t-tests.”
Baumann, B., Dános, P., Diekmann, S., Krell, D., Bielau, H., Geretsegger, C., Wurthmann, C., Bernstein, H., & Bogerts, B. (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050089 · Cited by 57 · cited 1×
“Finally our finding of no alteration in nigral tyrosine hydroxylase staining in patients with major depression extends previous findings in this patient population of altered tyrosine hydroxylase levels in the locus coeruleus (Baumann et al., 1999; Zhu et al., 1999; Gos et al., 2008).”
Striatal dopamine synthesis capacity in twins discordant for schizophrenia
Shotbolt, P., Stokes, P. R., Owens, S. F., Toulopoulou, T., Picchioni, M. M., Bose, S. K., Murray, R. M., & Howes, O. D. (2011) · Psychological Medicine · doi:10.1017/s0033291711000341 · Cited by 55 · cited 1×
“…al., 2000; Meyer-Lindenberg et al., 2002; McGowan et al., 2004; Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated baseline and stimulated striatal dopamine levels (Laruelle et al., 1996; Breier et al.,…”
Self-citationLodge, D. J., & Grace, A. A. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000113 · Cited by 53 · cited 1×
“…1996; Breier et al., 1997; Abi-Dargham et al., 2000) and meta-analysis (Howes et al., 2012b)], it seems likely that this reflects an increase in midbrain dopamine neuron population activity, in line with that seen in preclinical developmental models of schizophrenia (Lodge and Grace, 2007, 2011).”
In Vivo Regulation of DOPA Decarboxylase by Dopamine Receptors in Rat Brain
Cumming, P., Ase, A., Laliberté, C., Kuwabara, H., & Gjedde, A. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199711000-00014 · Cited by 49 · cited 1×
“Both enzymes are regulated, but the rate limiting step in dopamine synthesis is the conversion of tyrosine to dihydroxyphenyl-L-alanine (Zhu et al., 1993; Cumming et al., 1995, 1997; Fernstrom and Fernstrom, 2007).”
Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques
Brown, C., Karimi, M., Tian, L., Flores, H., Su, Y., Tabbal, S. D., Loftin, S. K., Moerlein, S. M., & Perlmutter, J. S. (2013) · Annals of Neurology · doi:10.1002/ana.23939 · Cited by 44 · cited 5×
“This extends to human findings in non-human primates, which have also shown this relationship between striatal and nigral 18 F-DOPA uptake (Brown et al., 2013).”
InfluentialArakawa, R., Ichimiya, T., Ito, H., Takano, A., Okumura, M., Takahashi, H., Takano, H., Yasuno, F., Kato, M., Okubo, Y., et al. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.04.009 · Cited by 37 · cited 1×
“Taken with evidence for increased dopamine D2, but not D3 or dopamine transporter, availability in the substantia nigra (Arakawa et al., 2009; Graff- Guerrero et al., 2009; Kessler et al., 2009; Mizrahi et al., 2011), these findings indicate that particular aspects of nigral dopaminergic function…”
Kim, E., Howes, O. D., Kim, B., Jeong, J. M., Lee, J. S., Jang, I., Shin, S., Turkheimer, F., Kapur, S., & Kwon, J. S. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.180 · Cited by 36 · cited 2×
“In the schizophrenia group the mean (SD) symptom severity scores were: total symptoms = 77.6 (47.6); positive symptoms = 38.3 (30); affective symptoms = 2.0 (3.9); negative symptoms = 31.9 (22.9).”
InfluentialSelf-citationGos, T., Krell, D., Bielau, H., Brisch, R., Trübner, K., Steiner, J., Bernstein, H., Jankowski, Z., & Bogerts, B. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-0825-8 · Cited by 35 · cited 2×
“To determine if age, sex, or post-mortem interval moderated the effect, a secondary analysis of variance was used to determine the effect of diagnostic group on staining score co-varying for these variables.”
Forsback, S. J., Niemi, R. E., Marjamäki, P., Eskola, O., Bergman, J., Grönroos, T. J., Haaparanta‐Solin, M., Haapalinna, A., Rinne, J. O., & Solin, O. H. (2003) · Synapse · doi:10.1002/syn.10293 · Cited by 33 · cited 2×
“Furthermore there is also a close, direct relationship between nigral 18 F-DOPA uptake and both nigral aromatic- L-amino acid decarboxylase activity and nigral dopamine cell numbers (Yee et al., 2000; Forsback et al., 2004; Brown et al., 2013).”
InfluentialYee, R. E., Huang, S., Stout, D. B., Irwin, I., Shoghi, K. I., Togaski, D. M., DeLanney, L. E., Langston, J. W., Satyamurthy, N., Farahani, K., et al. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.741147.x · Cited by 27 · cited 2×
“Furthermore there is also a close, direct relationship between nigral 18 F-DOPA uptake and both nigral aromatic- L-amino acid decarboxylase activity and nigral dopamine cell numbers (Yee et al., 2000; Forsback et al., 2004; Brown et al., 2013).”
Kim, E., Shidahara, M., Tsoumpas, C., McGinnity, C. J., Kwon, J. S., Howes, O. D., & Turkheimer, F. E. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.29 · Cited by 22
Self-citationTejedor‐Real, P., Biguet, N. F., Dumas, S., & Mallet, J. J. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10555 · Cited by 15 · cited 1×
“…effect of treatment on the post-mortem tyrosine hydroxylase levels (as all the schizophrenia subjects had taken antipsychotics), rodent studies indicate that antipsychotic treatment either does not alter (Perez-Costas et al., 2012) or reduces tyrosine hydroxylase levels (Tejedor-Real et al., 2003).”
Research works printed but not linked: 3
- Andreasen NC. Comprehensive assessment of symptoms and history. Iowa: University of Iowa College of Medicine; 1987. [Google Scholar]
- Asselin MCH, Howes OD, Osman S, Yau K, Grasby PM. Increase in striatal f-DOPA influx constants in patients at ultra high risk of psychosis are not due to changes in plasma OMFD concentrations. J Cereb Blood Flow Metab. 2007;27:PO01–03M. [Google Scholar]
- Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch Gen Psychiatry. 2012b;69:776–86. doi: 10.1001/archgenpsychiatry.2012.169. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
Cited by
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Schizophrenia, dopamine and the striatum: From biology to symptoms
McCutcheon, R. A., Abi-Dargham, A., & Howes, O. D. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.004 · Cited by 763
Self-citationGlutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
“…with some studies not finding significant differences from controls (Dao-Castellana et al., 1997; Elkashef et al., 2000; Shotbolt et al., 2011) whilst others have detected significant elevations (Howes et al., 2013a; McGowan et al., 2004; Meyer-Lindenberg et al., 2002; Reith et al., 1994).”
BackgroundSelf-citationThe Role of Genes, Stress, and Dopamine in the Development of Schizophrenia
Howes, O. D., McCutcheon, R., Owen, M. J., & Murray, R. M. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.014 · Cited by 601
Self-citationDopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Self-citation
Metadata
- Authors
- Howes, O. D., Williams, M., Ibrahim, K., Leung, G., Egerton, A., McGuire, P. K., & Turkheimer, F.
- Affiliations
- King's College London (GB)
- Hammersmith Hospital (GB)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-10-03
- Volume
- 136
- Issue
- 11
- Pages
- 3242-3251
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3808688
- OpenAlex
- W2148486359
- Cited by
- 198
- References
- 81
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 11 · 2023: 23 · 2022: 19 · 2021: 15 · 2020: 24 · 2019: 20 · 2018: 14 · 2017: 10 · 2016: 16 · 2015: 8 · 2014: 11
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Starr Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- schizophrenia, major depressive disorder, midbrain dopamine, substantia nigra, striatum, dopamine synthesis capacity, tyrosine hydroxylase, 18F-DOPA PET, dopaminergic dysfunction, symptom severity, postmortem brain, dopaminergic neurons, dopamine signaling, neuroimaging biomarkers
- MeSH terms
- Adult, Depressive Disorder, Major, Major Depressive Disorder, Dihydroxyphenylalanine, Dopamine, Female, Humans, Male, Middle Aged, Schizophrenia, Substantia Nigra, Tissue Banks, Tyrosine 3-Monooxygenase, Dopamine Agents, Neostriatum, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.